145 related articles for article (PubMed ID: 36497751)
1. Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users.
Huang G; Cheng W; Xu Y; Yang J; Jiang J; Pan X; Zhou X; Jiang J; Chai C
Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497751
[TBL] [Abstract][Full Text] [Related]
2. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
4. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
[TBL] [Abstract][Full Text] [Related]
6. HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy.
Persico M; Masarone M; Aglitti A; Armenante C; Giordano A; Guardiola A; Raimondi G; Contaldi C; Nigro C; Marena G; De Luna A
Liver Int; 2019 Oct; 39(10):1845-1851. PubMed ID: 31169953
[TBL] [Abstract][Full Text] [Related]
7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project.
Von den Hoff DW; Berden FAC; Drenth JPH; Schellekens AFA;
Addict Sci Clin Pract; 2022 Nov; 17(1):67. PubMed ID: 36451175
[TBL] [Abstract][Full Text] [Related]
9. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
[TBL] [Abstract][Full Text] [Related]
10. HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study.
Ryan P; Valencia J; Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ; Muñoz-Rivas N; Canorea I; Vázquez-Morón S; Resino S
Infect Dis Poverty; 2021 Aug; 10(1):111. PubMed ID: 34412695
[TBL] [Abstract][Full Text] [Related]
11. Acute searching and early diagnosis of HCV infected persons.
Husa Ml P; Husa P
Vnitr Lek; 2021; 67(8):455-458. PubMed ID: 35459364
[TBL] [Abstract][Full Text] [Related]
12. Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
McLeod A; Hutchinson SJ; Smith S; Leen C; Clifford S; McAuley A; Wallace LA; Barclay ST; Bramley P; Dillon JF; Fraser A; Gunson RN; Hayes PC; Kennedy N; Peters E; Templeton K; Goldberg DJ
HIV Med; 2021 May; 22(5):334-345. PubMed ID: 33350049
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.
Yi S; Mun P; Chhoun P; Chann N; Tuot S; Mburu G
Harm Reduct J; 2019 Apr; 16(1):29. PubMed ID: 31036011
[TBL] [Abstract][Full Text] [Related]
14. HCV prevalence and treatment outcomes among drug users in an outpatient center for drug addiction in Northern Italy.
Lanza A; Olivola M; Peschi G; Brondino N; Politi P
Ann Ist Super Sanita; 2023; 59(2):108-113. PubMed ID: 37337985
[TBL] [Abstract][Full Text] [Related]
15. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
16. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
van Santen DK; van der Helm JJ; Lindenburg K; Schim van der Loeff M; Prins M
Int J Drug Policy; 2017 Sep; 47():95-101. PubMed ID: 28606392
[TBL] [Abstract][Full Text] [Related]
17. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis.
Reed JR; Jordan AE; Perlman DC; Smith DJ; Hagan H
Syst Rev; 2016 Jul; 5(1):110. PubMed ID: 27401499
[TBL] [Abstract][Full Text] [Related]
18. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care.
Lazarus JV; Herranz A; Picchio CA; Villota-Rivas M; Rodríguez A; Alonso JM; Moratinos A; Perrotta A; Tegeo E; Bibiloni F; Buti M; Vilella À
BMJ Open; 2021 Oct; 11(10):e053394. PubMed ID: 34675021
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique.
Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S
Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
